EGFR TYROSINE KINASE INHIBITOR FOR TREATING CARDIOVASCULAR DYSFUNCTION

摘要

Use of a EGFR tyrosine kinase inhibitor in the manufacture of a medicament for the therapeutic or prophylactic treatment of cardiovascular dysfunction, especially cardiovascular dysfunction which is non-­proliferative in origin and/or characterised by abnormal vascular reactivity. Suitable inhibitors include derivatives of quinoline, of quinazoline, of isoquinoline and of indole derivatives. Inhibitors are preferably specific for EGFR.